文献速递眼底病与葡萄膜炎

TNFα抑制剂治疗非感染性眼内炎症的8年前瞻性监测研究

Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
PubMed 文献 · Br J Ophthalmol · 2019-03-12

该前瞻性队列研究随访43例接受英夫利西单抗或阿达木单抗治疗至少1年的非感染性葡萄膜炎或巩膜炎成人患者,从2006年至2014年每6个月评估。结果显示91%患者在中位1.2年后获得持续缓解,但51%经历一次复发,54%发生至少一次不良事件,9%发生严重不良事件。TNFi治疗与长期药物诱导缓解、视力稳定和激素减量相关。

要点

  • TNFi治疗非感染性眼内炎症可获得长期药物诱导缓解(91%)。
  • 复发常见,约半数患者经历一次复发(51%)。
  • 不良事件常见(54%),严重不良事件需住院或停药者占9%。

核心结论

  • TNFi治疗与眼内炎症的长期药物诱导缓解、视力稳定和皮质类固醇减量相关。
  • 不良事件常见但未出现新的安全信号,炎症复发在约半数治疗人群中发生。

研究设计与样本

  • 前瞻性队列研究,纳入85例接受TNFi的成人患者中的43例(34例英夫利西单抗,9例阿达木单抗),治疗至少1年,随访2006年至2014年。
  • 每6个月收集临床评估、用药、不良事件和激素挽救治疗史,每年评估SF-36和VCM1生活质量。

主要发现

  • 英夫利西单抗中位治疗时间3.2年(IQR 4.3),阿达木单抗中位治疗时间2.4年(IQR 1.8)。
  • 39例(91%)在中位1.2年后诱导持续缓解(每患者年0.5次)。
  • 22例(51%)经历一次复发,5例(12%)经历两次复发。
  • 23例(54%)发生至少一次不良事件,4例(9%)发生需住院或停药的严重不良事件。
  • 10例(23%)在开始TNFi后1.7年换用另一种TNFi或另一类生物制剂。

临床怎么用

  • TNFi可用于非感染性葡萄膜炎或巩膜炎的长期治疗,以实现激素减量和病情缓解。
  • 治疗中需监测不良事件和复发,约半数患者可能复发。

局限性

  • 样本量较小(43例),仅纳入治疗至少1年的患者,可能存在选择偏倚。
  • 研究为观察性队列,无对照组,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIM: To report the efficacy and tolerability of antitumour necrosis factor-alpha therapy (TNF inhibitors [TNFi]) in the management of non-infectious ocular inflammation, including uveitis and scleritis, in adult patients over an 8-year period. MATERIALS AND METHODS: This is a prospective cohort study of infliximab and adalimumab in the treatment of non-infectious ocular inflammatory disease. 43 of 85 adult patients on TNFi (34 infliximab, 9 adalimumab) for ≥1 year with non-infectious uveitis or scleritis were followed from 2006 to 2014. Clinical assessments, medication, adverse events and history of steroid rescues were collected at 6 monthly intervals. General quality of life (Short Form Health Survey (SF-36)) and visual quality of life (Vision-related quality of life Core Measure (VCM1)) were assessed annually. Outcome measures included rate of sustained remission, rate of relapse, systemic corticosteroid reduction, adverse events, and VCM1 and SF-36 scores. RESULTS: The median time on infliximab was 3.2 years (IQR 4.3) and on adalimumab was 2.4 years (IQR 1.8). Sustained remission was induced in 39 patients (91%) (0.5 per patient year) after a median of 1.2 years on a TNFi. 22 (51%) experienced one relapse, and 5 (12%) had two relapses. 23 (54%) had at least one adverse event; serious adverse events necessitating hospitalisation or cessation of medication occurred in four (9%) patients. 10 patients (23%) switched from the initiation of TNFi, at 1.7 years after starting, to another TNFi or another class of biologic therapy. CONCLUSION: TNFi treatment is associated with long-term drug-induced remission of ocular inflammation, visual stability and corticosteroid reduction. Adverse events were common and no new safety signals occurred. Relapse of inflammation occurs in half of the treated population.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sharma SM, Damato E, Hinchcliffe AE, et al. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2019. PMID: 30862619. doi:10.1136/bjophthalmol-2018-312767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。